vs
KKR Real Estate Finance Trust Inc.（KREF）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是KKR Real Estate Finance Trust Inc.的1.2倍（$30.3M vs $25.8M），KKR Real Estate Finance Trust Inc.净利率更高（-101.7% vs -221.3%，领先119.6%），REGENXBIO Inc.同比增速更快（43.0% vs -26.6%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -18.8%）
KKR房地产金融信托公司是全球投资机构KKR旗下的专业房地产金融平台，主要发起、收购并管理优先担保商业地产贷款组合，抵押物多为美国各地的优质机构级商业地产，通过贷款利息收入为投资者提供稳定的经风险调整后的回报。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
KREF vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.2倍
$25.8M
营收增速更快
RGNX
高出69.6%
-26.6%
净利率更高
KREF
高出119.6%
-221.3%
两年增速更快
RGNX
近两年复合增速
-18.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.8M | $30.3M |
| 净利润 | $-26.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -105.1% | -190.0% |
| 净利率 | -101.7% | -221.3% |
| 营收同比 | -26.6% | 43.0% |
| 净利润同比 | -229.6% | -31.2% |
| 每股收益（稀释后） | $-0.49 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KREFRGNX
| Q4 25 | $25.8M | $30.3M | ||
| Q3 25 | $25.3M | $29.7M | ||
| Q2 25 | $30.2M | $21.4M | ||
| Q1 25 | $31.3M | $89.0M | ||
| Q4 24 | $35.1M | $21.2M | ||
| Q3 24 | $37.0M | $24.2M | ||
| Q2 24 | $40.4M | $22.3M | ||
| Q1 24 | $39.1M | $15.6M |
净利润KREFRGNX
| Q4 25 | $-26.2M | $-67.1M | ||
| Q3 25 | $13.8M | $-61.9M | ||
| Q2 25 | $-29.7M | $-70.9M | ||
| Q1 25 | $-4.9M | $6.1M | ||
| Q4 24 | $20.3M | $-51.2M | ||
| Q3 24 | $-7.4M | $-59.6M | ||
| Q2 24 | $25.8M | $-53.0M | ||
| Q1 24 | $-3.1M | $-63.3M |
毛利率KREFRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率KREFRGNX
| Q4 25 | -105.1% | -190.0% | ||
| Q3 25 | 50.4% | -176.3% | ||
| Q2 25 | -101.3% | -296.3% | ||
| Q1 25 | -18.3% | 13.6% | ||
| Q4 24 | 55.8% | -242.1% | ||
| Q3 24 | -19.6% | -256.6% | ||
| Q2 24 | 63.3% | -251.3% | ||
| Q1 24 | -8.7% | -408.8% |
净利率KREFRGNX
| Q4 25 | -101.7% | -221.3% | ||
| Q3 25 | 54.4% | -208.3% | ||
| Q2 25 | -98.5% | -331.8% | ||
| Q1 25 | -15.5% | 6.8% | ||
| Q4 24 | 57.7% | -241.3% | ||
| Q3 24 | -20.0% | -246.3% | ||
| Q2 24 | 63.9% | -237.7% | ||
| Q1 24 | -7.9% | -405.4% |
每股收益（稀释后）KREFRGNX
| Q4 25 | $-0.49 | $-1.30 | ||
| Q3 25 | $0.12 | $-1.20 | ||
| Q2 25 | $-0.53 | $-1.38 | ||
| Q1 25 | $-0.15 | $0.12 | ||
| Q4 24 | $0.22 | $-0.99 | ||
| Q3 24 | $-0.19 | $-1.17 | ||
| Q2 24 | $0.29 | $-1.05 | ||
| Q1 24 | $-0.13 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $102.7M |
| 总资产 | $6.5B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资KREFRGNX
| Q4 25 | $84.6M | $230.1M | ||
| Q3 25 | $204.1M | $274.2M | ||
| Q2 25 | $107.7M | $323.3M | ||
| Q1 25 | $106.4M | $267.9M | ||
| Q4 24 | $104.9M | $234.7M | ||
| Q3 24 | $108.8M | $255.5M | ||
| Q2 24 | $107.2M | $290.4M | ||
| Q1 24 | $106.5M | $338.7M |
股东权益KREFRGNX
| Q4 25 | $1.2B | $102.7M | ||
| Q3 25 | $1.2B | $161.5M | ||
| Q2 25 | $1.2B | $213.7M | ||
| Q1 25 | $1.3B | $274.2M | ||
| Q4 24 | $1.3B | $259.7M | ||
| Q3 24 | $1.4B | $301.4M | ||
| Q2 24 | $1.4B | $348.3M | ||
| Q1 24 | $1.4B | $390.7M |
总资产KREFRGNX
| Q4 25 | $6.5B | $453.0M | ||
| Q3 25 | $6.5B | $525.2M | ||
| Q2 25 | $6.8B | $581.0M | ||
| Q1 25 | $6.6B | $490.9M | ||
| Q4 24 | $6.4B | $466.0M | ||
| Q3 24 | $6.8B | $519.1M | ||
| Q2 24 | $7.1B | $569.4M | ||
| Q1 24 | $7.3B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $72.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流KREFRGNX
| Q4 25 | $72.3M | $-52.3M | ||
| Q3 25 | $18.5M | $-56.0M | ||
| Q2 25 | $21.1M | $-49.3M | ||
| Q1 25 | $15.9M | $33.6M | ||
| Q4 24 | $132.6M | $-31.6M | ||
| Q3 24 | $49.1M | $-40.5M | ||
| Q2 24 | $30.6M | $-45.5M | ||
| Q1 24 | $34.5M | $-55.5M |
自由现金流KREFRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率KREFRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度KREFRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率KREFRGNX
| Q4 25 | — | — | ||
| Q3 25 | 1.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | 6.54× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KREF
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
